Association between baseline characteristics and RRP (univariate analyses). Values are median (interquartile range) unless otherwise specified.
| Characteristics | Total, n = 76 | RRP, n = 12 | Non-RRP, n = 64 | p* |
|---|---|---|---|---|
| Enrollment variables | ||||
| Age, yrs | 54.5 (44.0–62.5) | 53.5 (51.0–61.0) | 55 (42.5–62.5) | 0.85 |
| Female, % | 80.3 | 83.3 | 79.7 | 0.99 |
| Duration, mos | 3.0 (2.0–4.5) | 3.0 (2.0–6.0) | 3.0 (1.5–4.5) | 0.36 |
| RF, U/ml | 63.0 (20.0–170.0) | 104.9 (17.6–172.5) | 57.0 (21.5–169.0) | 0.60 |
| Positivity, % | 79.0 | 83.3 | 78.1 | 0.99 |
| ACPA, IU/ml | 66.8 (14.7–288.5) | 130.3 (28.6–304.9) | 55.5 (8.3–283.9) | 0.27 |
| Positivity, % | 82.9 | 100 | 79.7 | 0.11 |
| CRP, mg/dl | 0.54 (0.18–1.92) | 1.85 (0.36–2.93) | 0.52 (0.15–1.72) | 0.11 |
| Positivity, % | 75.0 | 91.7 | 71.9 | 0.27 |
| MMP-3, ng/ml | 72.6 (40.7–157.5) | 150.6 (93.3–237.0) | 63.2 (35.0–146.8) | 0.006 |
| Positivity, % | 50.0 | 72.7 | 46.0 | 0.19 |
| DAS28-CRP | 4.31 (3.77–5.38) | 5.02 (3.98–5.73) | 4.23 (3.77–5.36) | 0.23 |
| RAMRIS synovitis score | 9 (4–15) | 12 (5.5–19.5) | 9 (4–13) | 0.19 |
| Positivity, % | 100 | 100 | 100 | 1.00 |
| RAMRIS bone edema score | 1 (0–11) | 31.5 (5–39.5) | 1 (0–4.5) | < 0.0001 |
| Positivity, % | 57.9 | 91.7 | 51.6 | 0.011 |
| RAMRIS bone erosion score | 0 (0–3) | 3.5 (1.5–20) | 0 (0–2) | < 0.001 |
| Positivity, % | 47.4 | 91.7 | 39.1 | 0.001 |
| Genant-modified Sharp score | 0 (0–1.95) | 1.45 (0–2.65) | 0 (0–1.01) | 0.090 |
| Therapies, % | ||||
| MTX initiation | 53.9 | 50.0 | 54.7 | 0.99 |
| Biologics use within 6 mos | 7.9 | 8.3 | 7.8 | 1.00 |
| DAS28-EULAR moderate or good response at 3 mos | 72.4 | 75.0 | 67.2 | 0.42 |
↵* Fisher’s exact probability test or the Mann-Whitney U test. RRP: rapid radiographic progression; RF: rheumatoid factor; ACPA: anticitrullinated protein antibodies; CRP: C-reactive protein; MMP-3: matrix metalloprotease-3; DAS28: 28-joint Disease Activity Score; RAMRIS: Rheumatoid Arthritis Magnetic Resonance Imaging Scoring; MTX: methotrexate; EULAR: European League Against Rheumatism.